Smartest Doc
Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C Full Text
Bristol Myers-Squibb, 08/03/2012
Bristol–Myers Squibb Company announced that the Company has suspended study drug administration in an ongoing Phase II study of BMS–986094 (formerly known as INX–189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time.